Buy Like Buffett
Watchlist

Flagship explainer

How ADAPTIVE BIOTECHNOLOGIES CORPORATION makes its money

Start with a dollar of revenue and follow what the filing says remains.

revenueBranching filed flows with values and percentages directly labeled. Missing filing concepts are omitted rather than estimated.Revenue$277M · 100%Cost of revenue$71.4M · 26%Gross profit$206M · 74%Operating income−$57.1M · −21%Income before tax−$59.5M · −21%Income tax$0 · 0%Net income−$59.5M · −21%As of 2025-12-31 · 1 SEC filing sourceBuy Like Buffett · buylikebuffett.com

Honest partial: the filing did not provide a normalized tag for Research and development, Selling, general and administrative; those components are omitted, not plugged.

Table alternative
Filed lineValue% of revenueSource
$277M100%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-076902 · filed Feb 26, 2026
Cost of revenue$71.4M26%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-076902 · filed Feb 26, 2026
$206M74%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-076902 · filed Feb 26, 2026
−$57.1M−21%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-076902 · filed Feb 26, 2026
Income before tax−$59.5M−21%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-076902 · filed Feb 26, 2026
Income tax$00%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-076902 · filed Feb 26, 2026
−$59.5M−21%
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-076902 · filed Feb 26, 2026
Source:
  • 10-K · FY 2025Filing detailsAccession 0001193125-26-076902 · filed Feb 26, 2026
· event Dec 31, 2025 · retrieved Oct 16, 2026 · annual-row source set
Embed this chart

View the full ADAPTIVE BIOTECHNOLOGIES CORPORATION analysis at Buy Like Buffett